Asset
ALISPORIVIR
Enanta Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02173574 | phase1 | completed | 2014-08-01 | 2014-11-01 | Enanta Pharmaceuticals, Inc | Two-way Interaction Between Alisporivir and EDP239 |
FDA applications (0)
This company has no applications containing this asset.